AstraZeneca Expands US Manufacturing Footprint to Accelerate Ambitions in Next-Generation Cell Therapy Discovery and Development
February 07, 2024
February 07, 2024
WILMINGTON, Delaware, Feb. 7 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
AstraZeneca is investing $300 million in a state-of-the-art facility in Rockville, MD to launch its life-saving cell therapy platforms in the US for critical cancer trials and future commercial supply. More than 150 new highly skilled jobs will be created to initially focus on manufacturing T-cell therapies to enable clinical trials to be conducted around the world. Over time . . .
AstraZeneca is investing $300 million in a state-of-the-art facility in Rockville, MD to launch its life-saving cell therapy platforms in the US for critical cancer trials and future commercial supply. More than 150 new highly skilled jobs will be created to initially focus on manufacturing T-cell therapies to enable clinical trials to be conducted around the world. Over time . . .